Palvella Therapeutics

Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN 3.9% Rapamycin Anhydrous Gel

WAYNE, PA — Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, recently announced the planned pivotal Phase 3 study design of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), a topical mTOR …

Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN 3.9% Rapamycin Anhydrous Gel Read More
Palvella Therapeutics

Palvella Therapeutics Reports Topline Results from Pivotal Phase 3 VAPAUS Study of QTORIN 3.9% Rapamycin Anhydrous Gel

WAYNE, PA — Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, recently announced topline results from VAPAUS, a 24-week, randomized, double-blind, placebo-controlled pivotal Phase 3 study of QTORIN™ 3.9% rapamycin anhydrous …

Palvella Therapeutics Reports Topline Results from Pivotal Phase 3 VAPAUS Study of QTORIN 3.9% Rapamycin Anhydrous Gel Read More

Federal Trade Commission (FTC)

FTC Takes on Big Pharma: Blockbuster Drug Maker Amgen Faces Antitrust Lawsuit Over Acquisition of Horizon Therapeutics

The Federal Trade Commission recently announced it is seeking to block biopharmaceutical giant Amgen Inc. from acquiring Horizon Therapeutics plc, saying the deal would allow Amgen to leverage its portfolio …

FTC Takes on Big Pharma: Blockbuster Drug Maker Amgen Faces Antitrust Lawsuit Over Acquisition of Horizon Therapeutics Read More